SML3619

Linagliptin

Name: Linagliptin
Brand: SIGMA

≥98% (HPLC), dipeptidyl peptidase IV inhibitor, powder

Sinonimo/i:

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione, BI 1356, BI-1356, BI1356, Ondero

Slide 1 of 1

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Prezzi e disponibilità al momento non sono disponibili

Informazioni su questo articolo

Formula empirica (notazione di Hill):

C₂₅H₂₈N₈O₂

Numero CAS:

668270-12-0

Peso molecolare:

472.54

UNSPSC Code:

51111800

NACRES:

NA.77

MDL number:

MFCD14635356

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

Servizio Tecnico

Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.

Permettici di aiutarti

Nome del prodotto

Linagliptin, ≥98% (HPLC)

SMILES string

N5(C[C@@H](CCC5)N)c1[n](c2c([n]([c]([n]([c]2=O)Cc3nc4c(c(n3)C)cccc4)=O)C)n1)CC#CC

InChI

1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1

InChI key

LTXREWYXXSTFRX-QGZVFWFLSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

Quality Level

100

Categorie correlate

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo	SML3043	SML3526	SML3641
Sigma-Aldrich SML3619 Linagliptin	Sigma-Aldrich SML3043 XL188	Sigma-Aldrich SML3526 AZD8529	Sigma-Aldrich SML3641 Volasertib
form powder	form powder	form powder	form powder
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥95% (HPLC)
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
storage temp. -10 to -25°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. -10 to -25°C
solubility DMSO: 2 mg/mL, clear (Warmed)	solubility DMSO: 2 mg/mL, clear	solubility DMSO: 2 mg/mL, clear	solubility DMSO: 2 mg/mL, clear (Warmed)
color white to beige	color white to beige	color white to beige	color white to beige

Biochem/physiol Actions

Linagliptin is an orally active, competitive, potent and selective dipeptidyl peptidase IV (DPP4; DPP-IV) inhibitor (IC50 = 1 nM vs. 19 nM/sitagliptin, 24 nM/alogliptin, 50 nM/saxagliptin, 62 nM/vildagliptin) with no inhibitory potency against DPP-2/8/9 (IC50 >10 µM). Sitagliptin improves glucose tolerance and exhibits efficacy in diabetic rodent models in vivo (1-10 mg/kg via daily p.o. in mice and rats).

Orally active, competitive, potent and selective dipeptidyl peptidase IV (DPP-IV; DPP4) inhibitor that improves glucose tolerance in vivo.

hcodes

H412

pcodes

P273 - P501

Hazard Classifications

Aquatic Chronic 3

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

Leo Thomas et al.

The Journal of pharmacology and experimental therapeutics, 325(1), 175-182 (2008-01-29)

BI 1356 [proposed trade name ONDERO; (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] is a novel dipeptidyl peptidase (DPP)-4 inhibitor under clinical development for the treatment of type 2 diabetes. In this study, we investigated the potency, selectivity, mechanism, and duration of action of BI 1356

Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models.

Leo Thomas et al.

The Journal of pharmacology and experimental therapeutics, 328(2), 556-563 (2008-10-31)

Antidiabetic effects of dipeptidyl peptidase-4 (DPP-4) inhibitors are exerted by potentiation of the biological activity of incretin hormones like glucagon-like peptide (GLP)-1. BI 1356 [proposed trade name Ondero; (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] is a novel competitive, selective, potent, and long-acting DPP-4 inhibitor under

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.

Matthias Eckhardt et al.

Journal of medicinal chemistry, 50(26), 6450-6453 (2007-12-07)

A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Systematic structural variations have led to 1 (BI 1356), a highly potent, selective, long-acting

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica